Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain

S. S. Kaalund, E. N. Newburn, T. Ye, R. Tao, C. Li, A. Deep-Soboslay, M. M. Herman, Thomas Hyde, Daniel Weinberger, B. K. Lipska, Joel Kleinman

Research output: Contribution to journalArticle

Abstract

Dopamine 2 receptor (DRD2) is of major interest to the pathophysiology of schizophrenia (SCZ) both as a target for antipsychotic drug action as well as a SCZ-associated risk gene. The dopamine 1 receptor (DRD1) is thought to mediate some of the cognitive deficits in SCZ, including impairment of working memory that relies on normal dorsolateral prefrontal cortex (DLPFC) function. To better understand the association of dopamine receptors with SCZ, we studied the expression of three DRD2 splice variants and the DRD1 transcript in DLPFC, hippocampus and caudate nucleus in a large cohort of subjects (∼700), including patients with SCZ, affective disorders and nonpsychiatric controls (from 14th gestational week to 85 years of age), and examined genotype-expression associations of 278 single-nucleotide polymorphisms (SNPs) located in or near DRD2 and DRD1 genes. Expression of D2S mRNA and D2S/D2-long (D2L) ratio were significantly increased in DLPFC of patients with SCZ relative to controls (P<0.0001 and P<0.0001, respectively), whereas D2L, D2Longer and DRD1 were decreased (P<0.0001). Patients with affective disorders showed an opposite pattern: reduced expression of D2S (major depressive disorder, P<0.0001) and increased expression of D2L and DRD1 (bipolar disorder, P<0.0001). Moreover, SCZ-associated risk alleles at rs1079727, rs1076560 and rs2283265 predicted increased D2S/D2L expression ratio (P<0.05) in control individuals. Our data suggest that altered splicing of DRD2 and expression of DRD1 may constitute a pathophysiological mechanism in risk for SCZ and affective disorders. The association between SCZ risk-associated polymorphism and the ratio of D2S/D2L is consistent with this possibility.

Original languageEnglish (US)
Pages (from-to)1258-1266
Number of pages9
JournalMolecular Psychiatry
Volume19
Issue number12
DOIs
StatePublished - Dec 11 2014

Fingerprint

Mood Disorders
Single Nucleotide Polymorphism
Schizophrenia
Brain
Dopamine Receptors
Prefrontal Cortex
Caudate Nucleus
Major Depressive Disorder
Bipolar Disorder
Short-Term Memory
Antipsychotic Agents
Genes
Hippocampus
Alleles
Genotype
Messenger RNA

Keywords

  • bipolar disorder
  • depression
  • development
  • dopamine receptors
  • genotype
  • schizophrenia

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. / Kaalund, S. S.; Newburn, E. N.; Ye, T.; Tao, R.; Li, C.; Deep-Soboslay, A.; Herman, M. M.; Hyde, Thomas; Weinberger, Daniel; Lipska, B. K.; Kleinman, Joel.

In: Molecular Psychiatry, Vol. 19, No. 12, 11.12.2014, p. 1258-1266.

Research output: Contribution to journalArticle

Kaalund, S. S. ; Newburn, E. N. ; Ye, T. ; Tao, R. ; Li, C. ; Deep-Soboslay, A. ; Herman, M. M. ; Hyde, Thomas ; Weinberger, Daniel ; Lipska, B. K. ; Kleinman, Joel. / Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. In: Molecular Psychiatry. 2014 ; Vol. 19, No. 12. pp. 1258-1266.
@article{403084da0e4a41908e151c1a3e84365d,
title = "Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain",
abstract = "Dopamine 2 receptor (DRD2) is of major interest to the pathophysiology of schizophrenia (SCZ) both as a target for antipsychotic drug action as well as a SCZ-associated risk gene. The dopamine 1 receptor (DRD1) is thought to mediate some of the cognitive deficits in SCZ, including impairment of working memory that relies on normal dorsolateral prefrontal cortex (DLPFC) function. To better understand the association of dopamine receptors with SCZ, we studied the expression of three DRD2 splice variants and the DRD1 transcript in DLPFC, hippocampus and caudate nucleus in a large cohort of subjects (∼700), including patients with SCZ, affective disorders and nonpsychiatric controls (from 14th gestational week to 85 years of age), and examined genotype-expression associations of 278 single-nucleotide polymorphisms (SNPs) located in or near DRD2 and DRD1 genes. Expression of D2S mRNA and D2S/D2-long (D2L) ratio were significantly increased in DLPFC of patients with SCZ relative to controls (P<0.0001 and P<0.0001, respectively), whereas D2L, D2Longer and DRD1 were decreased (P<0.0001). Patients with affective disorders showed an opposite pattern: reduced expression of D2S (major depressive disorder, P<0.0001) and increased expression of D2L and DRD1 (bipolar disorder, P<0.0001). Moreover, SCZ-associated risk alleles at rs1079727, rs1076560 and rs2283265 predicted increased D2S/D2L expression ratio (P<0.05) in control individuals. Our data suggest that altered splicing of DRD2 and expression of DRD1 may constitute a pathophysiological mechanism in risk for SCZ and affective disorders. The association between SCZ risk-associated polymorphism and the ratio of D2S/D2L is consistent with this possibility.",
keywords = "bipolar disorder, depression, development, dopamine receptors, genotype, schizophrenia",
author = "Kaalund, {S. S.} and Newburn, {E. N.} and T. Ye and R. Tao and C. Li and A. Deep-Soboslay and Herman, {M. M.} and Thomas Hyde and Daniel Weinberger and Lipska, {B. K.} and Joel Kleinman",
year = "2014",
month = "12",
day = "11",
doi = "10.1038/mp.2013.165",
language = "English (US)",
volume = "19",
pages = "1258--1266",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain

AU - Kaalund, S. S.

AU - Newburn, E. N.

AU - Ye, T.

AU - Tao, R.

AU - Li, C.

AU - Deep-Soboslay, A.

AU - Herman, M. M.

AU - Hyde, Thomas

AU - Weinberger, Daniel

AU - Lipska, B. K.

AU - Kleinman, Joel

PY - 2014/12/11

Y1 - 2014/12/11

N2 - Dopamine 2 receptor (DRD2) is of major interest to the pathophysiology of schizophrenia (SCZ) both as a target for antipsychotic drug action as well as a SCZ-associated risk gene. The dopamine 1 receptor (DRD1) is thought to mediate some of the cognitive deficits in SCZ, including impairment of working memory that relies on normal dorsolateral prefrontal cortex (DLPFC) function. To better understand the association of dopamine receptors with SCZ, we studied the expression of three DRD2 splice variants and the DRD1 transcript in DLPFC, hippocampus and caudate nucleus in a large cohort of subjects (∼700), including patients with SCZ, affective disorders and nonpsychiatric controls (from 14th gestational week to 85 years of age), and examined genotype-expression associations of 278 single-nucleotide polymorphisms (SNPs) located in or near DRD2 and DRD1 genes. Expression of D2S mRNA and D2S/D2-long (D2L) ratio were significantly increased in DLPFC of patients with SCZ relative to controls (P<0.0001 and P<0.0001, respectively), whereas D2L, D2Longer and DRD1 were decreased (P<0.0001). Patients with affective disorders showed an opposite pattern: reduced expression of D2S (major depressive disorder, P<0.0001) and increased expression of D2L and DRD1 (bipolar disorder, P<0.0001). Moreover, SCZ-associated risk alleles at rs1079727, rs1076560 and rs2283265 predicted increased D2S/D2L expression ratio (P<0.05) in control individuals. Our data suggest that altered splicing of DRD2 and expression of DRD1 may constitute a pathophysiological mechanism in risk for SCZ and affective disorders. The association between SCZ risk-associated polymorphism and the ratio of D2S/D2L is consistent with this possibility.

AB - Dopamine 2 receptor (DRD2) is of major interest to the pathophysiology of schizophrenia (SCZ) both as a target for antipsychotic drug action as well as a SCZ-associated risk gene. The dopamine 1 receptor (DRD1) is thought to mediate some of the cognitive deficits in SCZ, including impairment of working memory that relies on normal dorsolateral prefrontal cortex (DLPFC) function. To better understand the association of dopamine receptors with SCZ, we studied the expression of three DRD2 splice variants and the DRD1 transcript in DLPFC, hippocampus and caudate nucleus in a large cohort of subjects (∼700), including patients with SCZ, affective disorders and nonpsychiatric controls (from 14th gestational week to 85 years of age), and examined genotype-expression associations of 278 single-nucleotide polymorphisms (SNPs) located in or near DRD2 and DRD1 genes. Expression of D2S mRNA and D2S/D2-long (D2L) ratio were significantly increased in DLPFC of patients with SCZ relative to controls (P<0.0001 and P<0.0001, respectively), whereas D2L, D2Longer and DRD1 were decreased (P<0.0001). Patients with affective disorders showed an opposite pattern: reduced expression of D2S (major depressive disorder, P<0.0001) and increased expression of D2L and DRD1 (bipolar disorder, P<0.0001). Moreover, SCZ-associated risk alleles at rs1079727, rs1076560 and rs2283265 predicted increased D2S/D2L expression ratio (P<0.05) in control individuals. Our data suggest that altered splicing of DRD2 and expression of DRD1 may constitute a pathophysiological mechanism in risk for SCZ and affective disorders. The association between SCZ risk-associated polymorphism and the ratio of D2S/D2L is consistent with this possibility.

KW - bipolar disorder

KW - depression

KW - development

KW - dopamine receptors

KW - genotype

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84922237436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922237436&partnerID=8YFLogxK

U2 - 10.1038/mp.2013.165

DO - 10.1038/mp.2013.165

M3 - Article

C2 - 24322206

AN - SCOPUS:84922237436

VL - 19

SP - 1258

EP - 1266

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 12

ER -